Bleeding in patients on anticoagulant therapy: The real utility of antidotes and how to manage bleeding in patients on new-generation oral anticoagulants;Hemorragias en pacientes anticoagulados: Utilidad real de los antídotos y modo de actuación con los nuevos anticoagulantes orales

Emergencias

Volumn 25, Issue 6, 2013, Pages 482-490

  Sánchez, Miquel ^a   Escolar, Ginés ^a   Reverter, Joan Carles ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Apixaban; Dabigatran; Hemorrhage; Oral anticoagulants; Rivaroxaban; Treatment; Vitamin K antagonists

Indexed keywords

EID: 84900295651     PISSN: 11376821     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Pollack CV Jr. New oral anticoagulants in the ED setting: a review. Am J Emerg Med. 2012;30:2046-54.
2. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019-26.
3. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Supl):160S-198S.
4. Poldermans D, Bax JJ, Boersma E, De Hert S, Eeckhout E, Fowkes G, et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in noncardiacsurgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in noncardiacSurgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur Heart J. 2009;30:2769-812.
5. Suero Méndez C. Los nuevos anticoagulantes orales en la fibrilación auricular: preguntas y respuestas para el urgenciólogo. Emergencias. 2013;25:123-36.
6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51.
7. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91.
8. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92.
9. European Medicines Agency (EMA). Pradaxa®, "Summary of Product Characteristics". (Consultado 4 Septiembre 2012). Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf
10. European Medicines Agency (EMA). Xarelto®, "Summary of Product Characteristics". (Consultado 20 Enero 2012). Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf.
11. European Medicines Agency (EMA). Eliquis®, "Summary of Product Characteristics". (Consultado 20 Junio 2011). Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf
12. CHMP post-authorisation summary of positive opinion for Eliquis. (Consultado 21 Septiembre 2012). Disponible en: http://www.ema.europa. eu/docs/en_GB/document_library/Summary_of_opinion/human/ 002148/WC500132869.pdf
13. Frank Peacock W, Gearhart MM, Mills RM. Emergency Management of Bleeding Associated With Old and New Oral Anticoagulants. Clin Cardiol. 2012;35:730-7.
14. Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM; Warfarin Reversal Consensus Group. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust. 2004;181:492-7.
15. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1998;114(Supl 5):445S-469S.
16. Wiedermann CJ, Stockner I. Warfarin-induced bleeding complications-clinical presentation and therapeutic options. Thromb Res. 2008;122(supl 2):S13-S18.
17. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003;107:1692-711.
18. Soedirman JR, De Bruijn EA, Maes RA, Hanck A, Gruter J. Pharmacokinetics and tolerance of intravenous and intramuscular phylloquinone (Vitamin K1) mixed micelles formulation. Br J Clin Pharmacol. 1996;41:517-23.
19. Desmettre T, Dehours E, Samama CM, Jhundoo S, Pujeau F, Guillaudin C, et al. Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice. Crit Care. 2012;16:R185.
20. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009;48:1-22.
21. Ordovás Baines JP, Climent Grana E, Jover Botella A, Valero García I. Pharmacokinetics and pharmacodynamics of new oral anticoagulants. Farm Hosp. 2009;33:125-33.
22. Härtter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa®) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol. 2013;75:1053-62.
23. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292-303.
24. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47:285-95.
25. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386-99.
26. Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol. 2012;26:27-32.
27. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011;50:675-86.
28. He K, Luettgen JM, Zhang D, He B, Grace JE Jr, Xin B, et al. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Eur J Drug Metab Pharmacokinet. 2011;36:129-39.
29. Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010;38:448-58.
30. Zhang D, He K, Raghavan N, Wang L, Crain EJ, He B, et al. Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits. J Thromb Thrombolysis. 2010;29:70-80.
31. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119:3016-23.
32. Madlener K, Hamm C. New anticoagulant drugs for atrial fibrillation. Feasibility and necessity of monitoring. Herz. 2012;37:378-83.
33. Kazmi RS, Lwaleed BA. New anticoagulants: how to deal with treatment failure and bleeding complications. Br J Clin Pharmacol. 2011;72:593-603.
34. Escolar Albadalejo G, García Frade J, López Fernández MF, Roldán Schilling V. Guía SEHH-SETH sobre los nuevos anticoagulantes orales (Sociedad Española de Hematología y Hemoterapia/Sociedad Española de trombosis y Hemostasia). (Consultado 10 Diciembre 2012). Disponible en: http://www.sehh.es/documentos/53/GUIA%20NAO%20MODIFICADA% 20diciembre%202012-R.pdf
35. Hemoclot® thrombin inhibitor assay (Hyphen BioMed, Neuville-sur-Oise, Francia). (Consultado 10 Diciembre 2012). Disponible en: www.hyphen-biomed.com.
36. Samama MM, Contant G, Spiro TE. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost. 2012;107:379-87.
37. Beauloye C, Dogné JM, Douxfils J, Goethals M, Hainaut P, Heidbuchel H, et al. Rivaroxaban. A Practical Guide V1.0. (Consultado 6 Julio 2012). Disponible en: http://www.thrombosisguidelinesgroup.be/sites/ default/files/Rivaroxaban%20Practical%20Guide%20V1%200_06-07-2012.pdf
38. Turpie AG, Kreutz R, Llau J, Norrving B, Haas S. Management consensus guidance for the use of rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost. 2012;108:876-86.
39. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104:1263-71.
40. Bauer KA. Reversal of antithrombotic agents. Am J Hematol. 2012;87 (Supl 1):S119-26.
41. Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87(Supl 1):S141-5.
42. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011;42:3594-9.
43. Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G, et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost. 2011;106:868-76.
44. Miesbach W, Seifried E. New direct oral anticoagulants-current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost. 2012;108:625-32.
45. Dzik WS. Reversal of drug-induced anticoagulation: old solutions and new problems. Transfusion. 2012;52(Supl 1):45S-55S.
46. van Ryn J, Ruehl D, Priepke H. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor Dabigatran, by recombinant factor VIIA or activated prothrombin complex concentrate. Copeenhagen, Dinamarca: 13th Congress of the European Hematology Association. Copenague; 2008. p 148.
47. Gruber A, Marzec UM, Holcomb JB. Potential of activated prothrombin complex concentrate and activated factor VII to reverse the Anticoagulant effects of rivaroxaban in primates. San Francisco, CA: 50th ASH Annual Meeting and Exposition; 2008.
48. Escolar G, Arellano-Rodrigo E, Reverter JC, Villalta J, Sanz V, Molina P, et al. Reversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: studies in vitro with circulating human blood. Circulation, June 2012. Disponible en: http://circ.ahajournals. org/content/early/2012/06/20/CIR.0b013e3182611cc2.shor.
49. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-9.
50. Clavé A, Fazilleau F, Dumser D, Lacroix J. Efficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: A case-control study in 70 patients. Orthop Traumatol Surg Res. 2012;98:484-90.
51. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: An open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49:259-68.
52. van Ryn J, Sieger P, Kink-Eiband M. Adsorption of Dabigatran etexilate in water or Dabigatran in pooled human plasma by activated charcoal in vitro. Nueva Orleans: 51st ASH Annual Meeting and Exposition; 2009.
53. Siegal DM, Crowther MA. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J. 2013;34:489-98.
54. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108:217-224.
55. Khoo TL, Weatherburn C, Kershaw G, Reddel CJ, Curnow J, Dunkley S. The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol. 2013;35:222-4.
56. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-47.